
Biosimilar FYB202 Confirms Therapeutic Equivalence to Ustekinumab for Plaque Psoriasis
Biosimilar FYB202 or ustekinumab-aauz (Otulfi; Fresenius Kabi) had no clinically relevant effect on efficacy, safety, or immunogenicity and demonstrated therapeutic equivalence to reference ustekinumab in patients with moderate to severe plaque psoriasis, …